Company: BIVIW
Filing Date: 2025-07-11
Form Type: S-1/A
Source: 0001520138-25-000205
Chunk: 114

Company: BIOVIE INC.
Filing Date: 2025-07-11
Form: S-1/A
Chunk 114
---
 clinical
operations, development, regulatory, and medical affairs. Prior to his time at Zynerba, Dr. Palumbo held senior worldwide governance roles
at Mitsubishi Tanabe Pharma in both the United States and Japan from April 2012 to June 2019, where he led medical science and translational
research across multiple therapeutic areas, and guided successful registrational programs for Radicava® (edaravone) for the treatment
of Amyotrophic Lateral Sclerosis. From April 2003 to March 2012, Dr. Palumbo was Global Head and Franchise Medical Leader for Psychiatry,
and the Interim Head of Global Neuroscience at Johnson & Johnson, where he led the medical teams who achieved successful global registrations
for Risperdal® (risperidone); Concerta® (methylphenidate HCL); and Invega® (paliperidone). He was Head of Psychiatry and Neurology
at Pharmanet for from April 2002 to April 2003. Dr Palumbo previously held industry positions in European Pharma with Sanofi-Synthelabo
from April 1999 to April 2002, Biotech at Cephalon, from April 1997 to April 1998, and from July 1989 to April 2002, he held senior leadership
and hospital administration roles at prestigious academic research institutions including Yale, Cornell, and the University of Pennsylvania.
He holds a Bachelor of Arts at the University of Pennsylvania and received his Doctor of Medicine at the George Washington University
School of Medicine. He was a Biological Sciences Training Program Fellow of the National Institutes of Health and Chief Resident for the
Abraham Ribicoff Clinical Neuroscience Research Unit at Yale University. Dr Palumbo has received Board Certification in Psychiatry and
Addiction Psychiatry.

<div align='center'>60</div>

Dr. Palumbo’s qualifications to serve as our Chief Medical Officer
is based on the decades and depth of experiences in the roles he has served in his medical profession and commercial experience in the
healthcare industry and biopharma industries.

Mr. Jim Lang, Chairman of the Board of Directors since March
2023 and has served as the Company’s director since 2016. He is currently CEO of EVERSANA, the leading commercialization services
company for the life sciences industry. In five years since he founded EVERSANA, it is now over $1B in revenue, with >7000 employees
across 40 global locations. He formerly served